Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. filed an initial ownership report for Chief Medical Officer Jeremy Brett Sokolove. He holds employee stock options to acquire 130,100 shares of common stock at an exercise price of $8.18 per share, expiring on October 31, 2035, with vesting beginning November 1, 2026 and continuing over the following three years. He also reports direct ownership of 27,900 shares of common stock, alongside restricted stock units that vest starting November 1, 2026, with remaining units vesting quarterly over three years, all subject to his continued service.
RA Capital Management and related parties report beneficial ownership of 12,399,706 shares of Vor Biopharma common stock, representing 19.9% of the class. This percentage is based on 54,185,582 shares outstanding as of March 30, 2026 and includes certain exercisable warrants and stock options.
The position reflects shares and warrants held primarily by RA Capital Healthcare Fund, including common stock warrants for up to 1,056,072 shares and pre-funded warrants for up to 10,000,000 shares, both subject to “beneficial ownership blocker” provisions that cap exercisability. Recent activity includes several open market sales by the Fund on April 2 and April 6, 2026 at weighted average prices between $16.25 and $19.09 per share.
RA Capital Healthcare Fund LP, through RA Capital Management, reported open-market sales of Vor Biopharma common stock. On April 2 and April 6, the Fund sold a total of 849,257 shares at prices ranging from $16.25 to $19.09 per share, using weighted-average pricing for each trade block.
After these transactions, the Fund indirectly held 4,555,741 Vor Biopharma shares, with RA Capital Management and related principals disclaiming beneficial ownership beyond their pecuniary interests. All reported holdings are described as being held directly by the Fund.
Vor Biopharma Inc. joint Schedule 13G filing reports that investment vehicles affiliated with TCG and Reporting Individual Chen Yu beneficially hold equity positions representing 10.5% (5,673,078 shares) of Vor's Common Stock. The filing bases the percentage on 54,185,582 shares, calculated from 48,847,504 shares outstanding as of March 23, 2026 plus 5,338,078 shares issued in an underwritten offering that closed March 30, 2026.
Vor Biopharma Inc. received an initial insider ownership report from TCG Crossover investment entities. The filing shows indirect holdings of 2,836,539 shares of Vor Biopharma common stock as of March 30, 2026, with TCG Crossover funds and their general partners reported as ten percent owners sharing voting, investment, and dispositive power.
RA Capital Management and affiliates filed Amendment No. 13 to update their ownership in Vor Biopharma Inc. They report beneficial ownership of 12,187,524 shares of common stock, representing 19.9% of the class, calculated on 54,185,582 shares outstanding as of March 30, 2026.
The change reflects an increase in Vor Biopharma’s outstanding shares rather than new purchases or sales by the reporting persons. The position includes common stock, common stock warrants for up to 1,056,072 shares, pre-funded warrants for up to 10,000,000 shares, and stock options held for the benefit of RA Capital, all subject to beneficial ownership blockers that limit exercise above specified ownership caps.
Vor Biopharma Inc. is repositioning itself as an autoimmune-focused biopharmaceutical company centered on telitacicept, a BAFF/APRIL‑targeting fusion protein in-licensed from RemeGen in June 2025. Telitacicept is already approved in China for SLE, RA and gMG, with additional Biologics License Applications pending for Sjögren’s disease and IgA nephropathy.
The company now leads global Phase 3 trials in generalized myasthenia gravis and Sjögren’s disease to support potential approvals in the United States, Europe and Japan, leveraging extensive Chinese Phase 3 data showing durable efficacy and a favorable safety profile. Earlier oncology and cell therapy programs, including trem-cel and VCAR33, have been discontinued and related intellectual property sold.
Under the telitacicept license, Vor paid a $125 million upfront (including a warrant for 16,000,000 shares) and owes up to $330 million in regulatory and $3.775 billion in sales milestones, plus tiered royalties. In March 2026 it agreed to a $75.0 million private placement of 5,338,078 shares at $14.05 per share with TCGX affiliates, and has granted registration rights for resale. A 1‑for‑20 reverse stock split was effected in September 2025, and 48,847,504 common shares were outstanding as of March 23, 2026.
Vor Biopharma Inc. entered into a securities purchase agreement with entities affiliated with TCGX for a private placement of 5,338,078 common shares at $14.05 per share, for gross proceeds of about $75.0 million. The closing is expected on or about March 30, 2026, subject to customary conditions.
After closing, Vor expects to have 54,185,582 common shares outstanding. The company plans to use the net proceeds to advance its clinical pipeline, including telitacicept programs, and for general corporate purposes. No placement agent was used. Vor also granted investors registration rights and will file a Form S-3 to register the resale of the new shares.
Vor Biopharma Inc. attracted a larger disclosed stake from RA Capital-affiliated investors through a change in warrant terms. RA Capital Management, its healthcare fund, and managers Peter Kolchinsky and Rajeev Shah now report beneficial ownership of 9,023,068 shares of common stock, representing 19.9% of the class based on 41,519,840 shares outstanding as of January 26, 2026. The increase stems from a March 12, 2026 notice raising the Pre-Funded Warrants’ maximum ownership percentage from 9.99% to 19.99%, which caused an additional 3,611,297 warrant shares to be counted as beneficially owned, effective March 13, 2026. The filing also notes ownership through common shares, common stock warrants, and stock options held for RA Capital’s benefit.
Vor Biopharma Inc. received an amended Schedule 13G from Verve Capital Limited, a Samoa-organized entity, reporting a significant passive stake. Verve Capital beneficially owns 4,297,464 shares of common stock through pre-funded warrants, subject to a 9.99% ownership blocker.
The 9.99% beneficial ownership is calculated using 38,720,196 shares of common stock outstanding as of December 18, 2025, plus 4,297,464 shares issuable upon exercise of the pre-funded warrants. Verve Capital certifies the holding is not for the purpose of changing or influencing control of Vor Biopharma.